New York, NYNCT05592938Now EnrollingIRB Ready

Breast Cancer Clinical Trial in New York, NY

Access cutting-edge breast cancer treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by University Health Network, Toronto

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer treatment provided free

Apply for This New York Location

Check if you qualify for this breast cancer clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Breast Cancer Study in New York

Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalent to longer fractionation schedules in the upfront treatment setting. These 1-week schedules are more convenient for patients, with fewer treatments and shorter overall treatment time. The investigators hypothesize that a 1-week ultra-hypofractionated rPBI regimen following breast-conserving surgery (BCS) for local recurrence or new primary breast cancer in the previously irradiated breast (LR) will be associated with acceptable toxicity at 1 year (\<13% grade \>3 toxicity).

Sponsor: University Health Network, Toronto

Who Can Participate

Inclusion Criteria

Age \> 18 years
In-breast recurrence or new primary (ductal carcinoma in situ (DCIS) or invasive carcinoma)
Tumour \<3.0 cm in greatest diameter on pathologic examination, including both invasive and non-invasive components
\>5 years after completion of prior adjuvant whole or partial breast radiotherapy (prior nodal radiotherapy permitted)
Clinically node negative
Negative margins (no tumour on ink)
Recovered from surgery with the incision completely healed and no signs of infection

Exclusion Criteria

Multicentric disease (patients with multifocal breast cancer in the same quadrant are eligible)
Tumour histology limited to lobular carcinoma only
Extensive intraductal component
Node positive or distant metastatic disease
Serious non-malignant disease (cardiovascular, pulmonary, systemic lupus erythematosus, scleroderma), which would preclude radiation treatment
Currently pregnant or lactating
Presence of an ipsilateral breast implant or pacemaker
Unable to commence radiation within 16 weeks of breast-conserving surgery (or last surgical procedure on the breast) or within 12 weeks from last cycle of adjuvant chemotherapy
Unable to clearly define the surgical cavity (oncoplastic procedures are permitted provided the tumor bed is well delineated with surgical clips).
Psychiatric disorders which would preclude obtaining informed consent or adherence to protocol
Grade II or more late skin toxicity from prior radiation evaluated and graded using CTCAE v5.0

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05592938) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in New York, NY

If you're searching for breast cancer treatment options in New York, NY, this clinical trial (NCT05592938) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in New York, NY

See all breast cancer clinical trials recruiting in New York — not just this study.

Browse Breast Cancer Trials in New York

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY